Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BFH772 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| BFH772 cream 1% | EXPERIMENTAL | - |
| Placebo to BFH772 cream 1% | PLACEBO_COMPARATOR | - |
| BFH772 ointment 1% | EXPERIMENTAL | - |
| Placebo to BFH772 ointment | PLACEBO_COMPARATOR | - |
| calcipotriol/betamethasone ointment | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| BFH772 | DRUG | - |
| Placebo | DRUG | - |
| calcipotriol/betamethasone | DRUG | - |
Inclusion Criteria: * Stable mild to moderate plaque psoriasis (BSA involvement \< 10% or PASI \< 10 * Category "mild to moderate" on PGA as according to the EMEA (CHMP 2004) (Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis), with or without arthri...
Top 12 of 13 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Johnson & Johnson | JNJ | 11 | PHASE3 | JNJ-77242113, Ustekinumab, Guselkumab |
| Bristol-Myers Squibb Company | BMY | 14 | PHASE3 | Deucravacitinib |
| AbbVie, Inc. | ABBV | 5 | PHASE3 | Risankizumab |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 3 | PHASE3 | Zasocitinib |
| Alumis Inc. | ALMS | 2 | PHASE3 | Envudeucitinib |
| Oruka Therapeutics, Inc. | ORKA | 4 | PHASE2 | ORKA-002, ORKA-001 |
| Can-Fite Biopharma Ltd | CANF | 1 | PHASE3 | Piclidenoson |
| Organon & Co. | OGN | 1 | PHASE3 | Tapinarof |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE3 | Ponesimod |
| Novartis AG Sponsored ADR | NVS | 4 | - | Secukinumab |
| Bausch Health Companies Inc. | BHC | 2 | - | Brodalumab |
| Merck & Co., Inc. | MRK | 1 | PHASE1 | MK-8644 |
BFH772 is an investigational small molecule developed by Novartis for the treatment of psoriasis. It has been studied in a Phase 1 clinical trial in patients with psoriasis and arthritis. It is not approved for any indication and remains in clinical development.
BFH772 targets KDR, also known as vascular endothelial growth factor receptor 2 (VEGFR2). It acts as an inhibitor of this receptor kinase. KDR inhibition is the proposed mechanism by which BFH772 is intended to affect psoriasis.
BFH772 is being developed by Novartis AG, which trades under the ticker NVS. Novartis is the sponsor of the clinical program evaluating BFH772 in dermatology, specifically for psoriasis.
BFH772 is in Phase 1 clinical development. The program has completed one Phase 1 trial and has no active trials. BFH772 is investigational and has not been approved by the FDA or any other regulatory authority for psoriasis or any other indication.
BFH772 has been evaluated in one completed Phase 1 trial, NCT00987870, titled Safety and Efficacy of BFH772 in Psoriasis Patients. The trial enrolled 15 adults in Germany and studied patients with psoriasis and arthritis. It was randomized, double-blind, and placebo-controlled.